Sandy Spring Bank Has $92,000 Stock Position in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Sandy Spring Bank boosted its stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 13.2% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 1,175 shares of the company’s stock after buying an additional 137 shares during the period. Sandy Spring Bank’s holdings in GE HealthCare Technologies were worth $92,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. Darwin Wealth Management LLC acquired a new position in GE HealthCare Technologies in the 3rd quarter valued at about $31,000. Continuum Advisory LLC grew its position in shares of GE HealthCare Technologies by 101.8% during the 3rd quarter. Continuum Advisory LLC now owns 333 shares of the company’s stock worth $31,000 after purchasing an additional 168 shares in the last quarter. Bank of Jackson Hole Trust acquired a new position in shares of GE HealthCare Technologies during the 4th quarter worth approximately $32,000. OFI Invest Asset Management acquired a new position in shares of GE HealthCare Technologies during the 4th quarter worth approximately $34,000. Finally, Flagship Wealth Advisors LLC acquired a new position in shares of GE HealthCare Technologies during the 4th quarter worth approximately $34,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

GE HealthCare Technologies Price Performance

Shares of NASDAQ:GEHC opened at $81.49 on Friday. The company has a market cap of $37.27 billion, a price-to-earnings ratio of 18.82, a PEG ratio of 3.19 and a beta of 1.13. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.04 and a quick ratio of 0.83. The firm has a 50 day simple moving average of $87.02 and a 200 day simple moving average of $86.02. GE HealthCare Technologies Inc. has a one year low of $74.51 and a one year high of $94.80.

GE HealthCare Technologies (NASDAQ:GEHC) last issued its quarterly earnings data on Thursday, February 13th. The company reported $1.45 EPS for the quarter, beating the consensus estimate of $1.26 by $0.19. The business had revenue of $5.32 billion during the quarter, compared to the consensus estimate of $5.33 billion. GE HealthCare Technologies had a net margin of 10.13% and a return on equity of 25.74%. Research analysts predict that GE HealthCare Technologies Inc. will post 4.68 earnings per share for the current fiscal year.

Analysts Set New Price Targets

GEHC has been the topic of a number of analyst reports. The Goldman Sachs Group upgraded shares of GE HealthCare Technologies from a “neutral” rating to a “buy” rating and increased their target price for the stock from $85.00 to $100.00 in a research report on Tuesday, March 11th. Wells Fargo & Company increased their target price on shares of GE HealthCare Technologies from $96.00 to $103.00 and gave the stock an “overweight” rating in a research report on Friday, February 14th. Citigroup increased their target price on shares of GE HealthCare Technologies from $103.00 to $110.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. Finally, Jefferies Financial Group raised shares of GE HealthCare Technologies from a “hold” rating to a “buy” rating and upped their price target for the stock from $95.00 to $103.00 in a report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, GE HealthCare Technologies has a consensus rating of “Moderate Buy” and an average price target of $98.75.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.